Nuvalent (NUVL) Accumulated Expenses (2020 - 2026)
Nuvalent's (NUVL) quarterly Accumulated Expenses came in at $8.2 million in Q1 2026, down 83.19% YoY from $48.9 million in Q1 2025, and down 86.54% on a QoQ basis from $61.0 million in Q4 2025.
Analysis
Nuvalent (NUVL) Accumulated Expenses (2020 - 2026) Analysis & Trends
Nuvalent (NUVL) has 7 years of Accumulated Expenses data on file, last reported at $8.2 million in Q1 2026.
- Quarterly Accumulated Expenses fell 83.19% year-over-year to $8.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.2 million (down 83.19% YoY) and the FY2025 annual result came in at $61.0 million, up 483.74% from the prior year.
- Accumulated Expenses eased to $8.2 million in Q1 2026, from $61.0 million in the prior quarter.
- In the past five years, Accumulated Expenses ranged from a high of $61.8 million in Q2 2025 to a low of $3.9 million in Q1 2022.
- A 5-year average of $21.7 million and a median of $12.3 million in 2022 frame the typical range for Accumulated Expenses.
- Annual changes were most pronounced in 2025 — Accumulated Expenses jumped 483.74% — and 2026, when it tumbled 83.19%.
- Tracing NUVL's Accumulated Expenses over 5 years: stood at $12.3 million in 2022, then slumped by 40.37% to $7.3 million in 2023, then surged by 42.67% to $10.5 million in 2024, then jumped by 483.74% to $61.0 million in 2025, then plunged by 86.54% to $8.2 million in 2026.
- The last three Accumulated Expenses figures came in at $8.2 million (Q1 2026), $61.0 million (Q4 2025), and $11.8 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Nuvalent | 9.75 Bn | 9.75 Bn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2026 | 58.92 Mn |
| Dec 31, 2025 | 61.01 Mn |
| Sep 30, 2025 | 67.14 Mn |
| Jun 30, 2025 | 61.81 Mn |
| Mar 31, 2025 | 48.87 Mn |
| Dec 31, 2024 | 48.80 Mn |
| Sep 30, 2024 | 35.20 Mn |
| Jun 30, 2024 | 30.79 Mn |
| Mar 31, 2024 | 20.03 Mn |
| Dec 31, 2023 | 22.55 Mn |
| Sep 30, 2023 | 19.32 Mn |
| Jun 30, 2023 | 12.68 Mn |
| Mar 31, 2023 | 10.59 Mn |
| Dec 31, 2022 | 12.29 Mn |
| Sep 30, 2022 | 8.36 Mn |
| Jun 30, 2022 | 6.01 Mn |
| Mar 31, 2022 | 3.88 Mn |
| Dec 31, 2021 | 5.89 Mn |
| Sep 30, 2021 | 4.31 Mn |
| Jun 30, 2021 | 2.03 Mn |